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BIOMEDICAL & PHARMACEUTICAL SCIENCES 421 (MEDICINAL CHEMISTRY I)         AUTUMN, 2005 
 
INSTRUCTORS: 
  David Freeman, Office: SB 308 Office Phone: 243-4772        Home Phone: 728-6551 
  E-mail: david.freeman@umontana.edu  
  Todd Cochran,  Office: SB 353  Office Phone: 243-4941 
  E-mail:  todd.cochran@umontana.edu
 
EXAMS AND GRADING: 
  First Exam:  Friday, Sept. 30  . . . . . .   60 points 
  Second Exam: Friday, Nov. 4   . . . . . .   80 points 
  Third Exam:  Friday, Dec. 2   . . . . . .   80 points 
  Final Exam:  Wednesday, Dec. 14, 10 a.m. . . . . . 100 points  
  10 Point Quizzes: Best 5 out of 6 scores . . . . . .   50 points 
  Total Points:  370        90-100% = A        80-89 % = B        70-79 % = C        65-69 % = D 
    * All EXAMS are comprehensive 
    * All exams and quizzes must be taken at scheduled times 
    * Instructor must be informed BEFORE missing a scheduled exam period  
     and must be based on GOOD REASONS  
    * Missed exam periods must be made up within 2 days 
    * Corrections to exams or quizzes must be requested within 7 days after returning 
 
STUDENT PERFORMANCE OBJECTIVES: 
1) Identify organic functional groups and know their polar/lipophilic and acid/base properties  
2) Know the relationships between organic functional groups and biological activity 
3) Know the possible modes of metabolism in the body for organic functional groups 
4) Know the chemical structures of important neurotransmitters or hormones and the biochemical 
    pathways for their syntheses and metabolism  
 5) Know the major biochemical events triggered by the activation of receptors important for drug action  
 6) Given the chemical structure of a drug, know its pharmacologic or therapeutic class  
 7) Given the chemical structure of a drug, know important chemical features (acid/base or lipophilic  
     properties, chemical groups affecting absorption, distribution, or metabolism, chemical groups 
     affecting potency or receptor interaction, chemical groups affecting storage or formulation) 
     that contribute to the drug's pharmacological activity  
 8) Given the chemical structure of a drug, know important chemical changes that will predictably 
     alter the pharmacological properties (potency, duration of action, etc.) of the drug  
 9) Given the chemical structure of a drug, know the important biological receptors it interacts 
     with and the biochemical events produced by these interactions  
 10) Given the common or generic name of a drug, know its pharmacologic or therapeutic class, 
     some of its important chemical properties (structural skeleton or chemical class, acid/base, etc.), 
     the receptors it interacts with and the biochemical events produced by these interactions  
  
TEXTBOOK:  Goodman & Gilman's "The Pharmacological Basis of Therapeutics", Tenth Edition  
 
Reading 
in TEXT 
 
 I. Acid-Base Partitioning and Solubility of Drugs 
3-4  A. Distribution ratio for acid/base drugs between two membrane bound compartments 
  B. Altering urinary pH to avoid crystalluria, uric acid kidney stones, or drug toxicity 
             C. Producing inorganic and organic salts of drugs for parenteral administration 
 
 
 
 
Reading 
in TEXT  
 
  II. Protein Structure and Function 
  A. Polar/lipophilic properties of amino acids 
  B. Types of intramolecular interactions determining the tertiary structure of proteins 
  C. General types of topography for proteins (e.g. transmembrane helices, beta-sheets, etc.) 
  D. General types of biochemical alteration of proteins (e.g. phosphorylation) that 
       alter tertiary structure and control protein function 
  
12-18 III. Drug Metabolism 
  A. Phase I biotransformations – Cytochrome P450  
  B. Phase II biotransformations  
  C. Pro-drugs 
  D. Variation in drug metabolism – pharmacogenetics  
 
   IV.  Biochemical Processes Affecting Drugs and Pharmacological Activity 
  A.  Processes Affecting Drug Distribution  
3-4, 8-10  1.  Non-specific binding sites and plasma protein binding 
  B.  Processes Affecting Drug Action at the Active Site 
31-36   1. Structural families of receptors 
   2.  Binding events initiating the pharmacological response 
    a.  Occupancy and conformational changes of receptor  
    b.  Agonist vs. antagonist events  
   3.  Events propagating and amplifying pharmacological response 
   4.  Events terminating the pharmacological response 
 
 V.  Processes and Overview of Drugs Affecting Cholinergic Receptors 
121-129 A. Biochemical Events at the Cholinergic Synapse  
Table 6-2  1.  Synthesis and metabolism of acetylcholine  
   2.  Muscarinic and nicotinic receptors  
   3.  Processes following receptor activation  
  B.  Overview on Cholinergic Drugs 
 
 VI.  Muscarinic Receptor Agonists 
155-160 A.  Chemistry of Acetylcholine 
   1.  Important functional groups  
   2.  Conformations of acetylcholine 
  B.  SAR and Chemistry of Selected Agonists  
   * METHACHOLINE  CARBACHOL  BETHANECHOL  PILOCARPINE  CEVIMELINE * 
  
 VII.  Anticholinesterase Agents  
175-181 A.  Mechanism of Acetylcholine Hydrolysis  
   1.  Individual steps involved in hydrolysis  
   2.  Rates of reaction steps  
  B.  Mechanisms of Cholinesterase Inhibition  
   1.  Competitive binding at active site  
   2.  Covalent binding at active site  
  C.  SAR and Chemistry of Cholinesterase Inhibitors  
   1.  Natural product and model agent   * PHYSOSTIGMINE *  
   2.  Competitive inhibitors  * EDROPHONIUM * 
   3.  Carbamates - "reversible" inhibitors * NEOSTIGMINE   PYRIDOSTIGMINE * 
   4.  Organophosphates - "irreversible" inhibitors  
    * ECHOTHIOPHATE  ISOFLUROPHATE  PARATHION  MALATHION * 
185  D.  Reactivation of Inhibited Cholinesterase    * PRALIDOXIME * 
 
Reading 
in TEXT
 VIII.  Cholinergic Antagonists  
162-164 A.  Muscarinic Blocking Agents  
   1.  Natural product and model agent - atropine  
   2.  SAR and chemistry of selected antimuscarinic agents  
        a.  Tertiary amines  
   * ATROPINE  SCOPOLAMINE  HOMATROPINE  DICYCLOMINE  CYCLOPENTOLATE  
        b.  Quaternary amines  
   * GLYCOPYRROLATE  METHANTHELINE  PROPANTHELINE   IPRATROPIUM * 
 
 IX.  Agents Acting At Nicotinic Receptors 
193-194 A. Properties of the Nicotinic Cholinergic Receptor 
194-199 B.  Neuromuscular blocking agents  
   1.  Natural product and model agent   * TUBOCURARINE * 
   2.  Competitive agents   * MIVACURIUM   ATRACURIUM   PANCURONIUM *  
   3.  Depolarizing agents   * DECAMETHONIUM  SUCCINYLCHOLINE  * 
208-211 C.  Ganglionic blocking agents   * HEXAMETHONIUM  TRIMETHAPHAN   MECAMYLAMINE * 
 
   X.  Processes and Overview of Drugs Affecting Adrenergic Receptors 
129-142 A.  Biochemical Events at the Adrenergic Synapse  
   1.  Synthesis and storage of norepinephrine  
   2.  Termination and metabolism of catecholamines 
   3.  Alpha and beta receptors and subtypes  
   4.  Processes following receptor activation  
  B.  Overview on Adrenergic Drugs 
 
 XI.  Adrenergic Receptor Agonists 
216-220 A.  Chemistry of Norepinephrine and Epinephrine  
   1.  Oxidative and acid/base properties  
   2.  Stereochemistry 
  B.  SAR and Chemistry of Selected Agonists  
   1.  Differentiating alpha and beta activity  
   2.  Decreasing metabolism  
   3.  Peripheral vs. CNS effects  
   4.  Direct and indirect effects  
    * DOPAMINE  ISOPROTERENOL  TERBUTALINE  METAPROTERENOL * 
    * ALBUTEROL  SALMETEROL  EPHEDRINE  PHENYLPROPANOLAMINE * 
    * RITODRINE   CLONIDINE   AMPHETAMINE  TETRAHYDROZOLINE * 
    * METHYLPHENIDATE   DOBUTAMINE   METHOXAMINE  PHENYLEPHRINE 
    * PHENTERMINE  METHYLPHENIDATE  PEMOLINE  COCAINE * 
   5.  Physiological and biochemical mechanisms 
 
 XII.  Adrenergic Receptor Antagonists  
242-246 A.  Alpha Blocking Agents  
   1.  Chemistry of haloalkylamines  * PHENOXYBENZAMINE * 
   2.  Chemistry of imidazolines  * PHENTOLAMINE   TOLAZOLINE * 
   3.  Selective blockers  * PRAZOSIN   TERAZOSIN   DOXAZOSIN * 
       * TAMSULOSIN    ALFUZOSIN * 
249-253 B.  Beta Blocking Agents  
   1.  Nonselective blockers   * PROPRANOLOL   NADOLOL   TIMOLOL * 
              * PINDOLOL   CARTEOLOL *  
   2.  Selective blockers  * METOPROLOL  ATENOLOL  ACEBUTOLOL   ESMOLOL *  
   3.  Blockers with intrinsic sympathomimetic activity (ISA blockers) 
   4.  Combined alpha and beta blocker   * LABETALOL   CARVEDILOL * 
Reading 
in TEXT
 
 XIII.  Local and General Anesthetics 
367-374 A.  SAR and Chemistry of Local Anesthetic Agents 
   1.  Natural product and model compound    * COCAINE * 
   2.  Synthetic esters and amides    
    * PROCAINE  LIDOCAINE  TETRACAINE  ETIDOCAINE * 
    * BENZOCAINE   PRAMOXINE * 
  B.  Nonspecific and Specific Effects on Neural Membranes 
  C.  Factors Affecting Activity of Agents 
  D.  Adverse effects and metabolism  
 337-341 E.  Structure and Chemical Properties of General Anesthetic Agents 
   * DIETHYL ETHER   NITROUS OXIDE   HALOTHANE   ISOFLURANE * 
 
 XIV.  Sedative/Hypnotic Agents 
400-405 A.  Benzodiazepines 
Table 17-2  1.  Structure, Chemical Properties, and SAR 
409-412  2.  Biochemical effects 
    * DIAZEPAM  CHLORDIAZEPOXIDE  FLURAZEPAM  OXAZEPAM * 
    * TRIAZOLAM  MIDAZOLAM  LORAZEPAM   ZOLPIDEM  ZALEPLON * 
412-416 B.  Barbiturates 
Table 17-4  1.  Chemical properties and SAR of agents 
   2.  Biochemical effects 
    * PHENOBARBITAL   PENTOBARBITAL   SECOBARBITAL * 
    * BUTABARBITAL THIOPENTAL * 
420  C.  Non-barbiturates * CHLORAL HYDRATE  * 
 
 XV.  Antineoplastic Agents 
1389-1392 A.  Chemistry and Mechanisms of Action for Alkylating and Cross-linking Agents 
* MECHLORETHAMINE  CHLORAMBUCIL  CYCLOPHOSPHAMIDE  IFOSFAMIDE * 
   * BUSULFAN  CARMUSTINE   LOMUSTINE * 
1432-1434  * CISPLATIN   CARBOPLATIN   OXALIPLATIN * 
  B.  Mechanisms of Action for Antimetabolite Agents 
1399-1407  * METHOTREXATE  LEUCOVORIN  FLUOROURACIL   PEMETREXED * 
1408-1414  *  CYTARABINE   GEMCITABINE   CAPECITABINE    MERCAPTOPURINE * 
  C.  Mechanisms of Action for Natural Products and Miscellaneous Agents 
1417-1420  * VINCRISTINE   VINBLASTINE  PACLITAXEL  DOCETAXEL * 
1421, 1431  *  ETOPOSIDE    ASPARAGINASE *    
  D.  Mechanisms of Action for Agents Inhibiting Enzymes 
1422-1425  * IRINOTECAN   TOPOTECAN   IMATINIB   GEFTINIB * 
1435, 1439  * HYDROXYUREA   ANASTROZOLE   LETROZOLE * 
  E.  Mechanisms of Action for Antibiotic Type Agents 
1426-1430  * DOXORUBICIN   DAUNORUBICIN   IDARUBICIN   BLEOMYCIN * 
 
